Display Settings:

Format

Send to:

Choose Destination
Oncoimmunology. 2013 Apr 1;2(4):e23432.

Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response.

Author information

  • 1Research Unit for Cellular Immunotherapy; The Institute of Physical and Chemical Research (RIKEN); Research Center for Allergy and Immunology (RCAI); Yokohama, Japan.

Abstract

Both innate and adaptive immunity underpin cancer immunosurveillance. To stimulate both these arms of the immune system, we used allogeneic cells loaded with natural killer T (NKT) cell ligands and expressing tumor-associated antigens, resulting in NKT cell activation, dendritic-cell maturation and ultimately in the elicitation of adaptive T-cell responses. This approach holds great promise for the development of novel anticancer immunotherapies.

KEYWORDS:

adjuvant effects; cross-presentation; dendritic cells; iNKT cells; α-galactosylceramide

PMID:
23734303
[PubMed]
PMCID:
PMC3654573
Free PMC Article

Images from this publication.See all images (1)Free text

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk